| Symbol | BCAX |
|---|---|
| Name | BICARA THERAPEUTICS INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 245 MAIN,STREET, CAMBRIDGE, Massachusetts, 02142, United States |
| Telephone | 617-468-4219 |
| Fax | — |
| — | |
| Website | https://www.bicara.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0002023658 |
| Description | Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Our lead program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. Ficerafusp alfa is initially being developed in head and neck squamous cell carcinoma, or HNSCC, where there remains a significant unmet need. We intend to initiate a pivotal Phase 2/3 trial of ficerafusp alfa in combination with pembrolizumab as a first-line therapy in recurrent/metastatic HNSCC excluding HPV-positive patients with oropharyngeal squamous cell carcinoma late in the fourth quarter of 2024 or early in the first quarter of 2025. Additional info from NASDAQ: |
New Form SCHEDULE 13G - Bicara Therapeutics Inc. <b>Filed:</b> 2026-07-27 <b>AccNo:</b> 0002012383-26-002268 <b>Size:</b> 10 KB
Read more📋 Lara Meisner (Officer) plans to sell 1K shares of BICARA THERAPEUTICS INC. (at $29.77 each, total $30K) Filed: Jul 07, 2026 | ID: 006915
Read moreBicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Read more📋 DAVID RABEN (Officer) plans to sell 50K shares of BICARA THERAPEUTICS INC. (at $26.49 each, total $1.3M) Filed: Jun 25, 2026 | ID: 006490
Read moreRA CAPITAL MANAGEMENT, L.P. 🟢 acquired 19.5K shares (1 derivative) of Bicara Therapeutics Inc. (BCAX) at $20.56 Transaction Date: Jun 09, 2026 | Filing ID: 000618
Read moreDirector Bowden Christopher 🟢 acquired 19.5K shares (1 derivative) of Bicara Therapeutics Inc. (BCAX) at $20.56 Transaction Date: Jun 09, 2026 | Filing ID: 042255
Read moreDirector Haviland Kate 🟢 acquired 19.5K shares (1 derivative) of Bicara Therapeutics Inc. (BCAX) at $20.56 Transaction Date: Jun 09, 2026 | Filing ID: 042253
Read moreDirector Mazumdar-Shaw Kiran 🟢 acquired 19.5K shares (1 derivative) of Bicara Therapeutics Inc. (BCAX) at $20.56 Transaction Date: Jun 09, 2026 | Filing ID: 042251
Read moreDirector Robertson Scott M. 🟢 acquired 19.5K shares (1 derivative) of Bicara Therapeutics Inc. (BCAX) at $20.56 Transaction Date: Jun 09, 2026 | Filing ID: 042249
Read moreDirector POWELL MICHAEL 🟢 acquired 19.5K shares (1 derivative) of Bicara Therapeutics Inc. (BCAX) at $20.56 Transaction Date: Jun 09, 2026 | Filing ID: 042248
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07552558 | Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for H… | Phase1 | Head and Neck Squamous Cell Carcinoma | Not_Yet_Recruiting | 2026-06-30 | 2033-08-31 | ClinicalTrials.gov |
| NCT07529873 | Phase II Study of Ficerafusp Alfa in Combination With Nivolumab in Patients Wit… | Phase2 | Squamous Cell Carcinoma of Head and Neck (SCCHN) | Not_Yet_Recruiting | 2026-05-01 | 2030-12-01 | ClinicalTrials.gov |
| NCT07465276 | Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC | Phase2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | Recruiting | 2026-03-26 | 2030-04-30 | ClinicalTrials.gov |
| NCT06788990 | FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination Wit… | Phase2 | Metastatic Head and Neck Squamous Cell Carcinoma | Recruiting | 2025-01-28 | 2029-07-01 | ClinicalTrials.gov |
| NCT04429542 | Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Thera… | Phase1 | Head and Neck Squamous Cell Carcinoma | Recruiting | 2020-06-01 | 2027-06-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE2 | Metastatic Head and Neck Squamous Cell Carcinoma | RECRUITING | NCT06788990 |
| Pembrolizumab (KEYTRUDA®) | Other | Phase PHASE2 | Metastatic Head and Neck Squamous Cell Carcinoma | RECRUITING | NCT06788990 |
| Ficerafusp alfa | Other | Phase PHASE2 | Metastatic Head and Neck Squamous Cell Carcinoma | RECRUITING | NCT06788990 |
| Placebo | Other | Phase PHASE2 | Metastatic Head and Neck Squamous Cell Carcinoma | RECRUITING | NCT06788990 |
| Pembrolizumab (KEYTRUDA®) | Other | Phase PHASE2 | Metastatic Head and Neck Squamous Cell Carcinoma | RECRUITING | NCT06788990 |
| Ficerafusp alfa | Other | Phase PHASE2 | Metastatic Head and Neck Squamous Cell Carcinoma | RECRUITING | NCT06788990 |
| Ficerafusp alfa | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma | NOT_YET_RECRUITING | NCT07552558 |
| Pembrolizumab | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma | NOT_YET_RECRUITING | NCT07552558 |
| Hypofractionated Stereotactic Body Radiotherapy (SBRT) | Drug | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma | NOT_YET_RECRUITING | NCT07552558 |
| Placebo | Other | Phase PHASE2 | Metastatic Head and Neck Squamous Cell Carcinoma | RECRUITING | NCT06788990 |
| Pembrolizumab (KEYTRUDA®) | Other | Phase PHASE2 | Metastatic Head and Neck Squamous Cell Carcinoma | RECRUITING | NCT06788990 |
| Ficerafusp alfa | Other | Phase PHASE2 | Metastatic Head and Neck Squamous Cell Carcinoma | RECRUITING | NCT06788990 |
| Placebo | Other | Phase PHASE2 | Metastatic Head and Neck Squamous Cell Carcinoma | RECRUITING | NCT06788990 |
| Pembrolizumab (KEYTRUDA®) | Other | Phase PHASE2 | Metastatic Head and Neck Squamous Cell Carcinoma | RECRUITING | NCT06788990 |
| Ficerafusp alfa | Other | Phase PHASE2 | Metastatic Head and Neck Squamous Cell Carcinoma | RECRUITING | NCT06788990 |
| Placebo | Other | Phase PHASE2 | Metastatic Head and Neck Squamous Cell Carcinoma | RECRUITING | NCT06788990 |
| Pembrolizumab (KEYTRUDA®) | Other | Phase PHASE2 | Metastatic Head and Neck Squamous Cell Carcinoma | RECRUITING | NCT06788990 |
| Ficerafusp alfa | Other | Phase PHASE2 | Metastatic Head and Neck Squamous Cell Carcinoma | RECRUITING | NCT06788990 |
| Placebo | Other | Phase PHASE2 | Metastatic Head and Neck Squamous Cell Carcinoma | RECRUITING | NCT06788990 |
| Pembrolizumab (KEYTRUDA®) | Other | Phase PHASE2 | Metastatic Head and Neck Squamous Cell Carcinoma | RECRUITING | NCT06788990 |
| Ficerafusp alfa | Other | Phase PHASE2 | Metastatic Head and Neck Squamous Cell Carcinoma | RECRUITING | NCT06788990 |
| Placebo | Other | Phase PHASE2 | Metastatic Head and Neck Squamous Cell Carcinoma | RECRUITING | NCT06788990 |
| Pembrolizumab (KEYTRUDA®) | Other | Phase PHASE2 | Metastatic Head and Neck Squamous Cell Carcinoma | RECRUITING | NCT06788990 |
| Ficerafusp alfa | Other | Phase PHASE2 | Metastatic Head and Neck Squamous Cell Carcinoma | RECRUITING | NCT06788990 |
| Placebo | Other | Phase PHASE2 | Metastatic Head and Neck Squamous Cell Carcinoma | RECRUITING | NCT06788990 |
| Pembrolizumab (KEYTRUDA®) | Other | Phase PHASE2 | Metastatic Head and Neck Squamous Cell Carcinoma | RECRUITING | NCT06788990 |
| Ficerafusp alfa | Other | Phase PHASE2 | Metastatic Head and Neck Squamous Cell Carcinoma | RECRUITING | NCT06788990 |
| Placebo | Other | Phase PHASE2 | Metastatic Head and Neck Squamous Cell Carcinoma | RECRUITING | NCT06788990 |
| Pembrolizumab (KEYTRUDA®) | Other | Phase PHASE2 | Metastatic Head and Neck Squamous Cell Carcinoma | RECRUITING | NCT06788990 |
| Ficerafusp alfa | Other | Phase PHASE2 | Metastatic Head and Neck Squamous Cell Carcinoma | RECRUITING | NCT06788990 |
| Placebo | Other | Phase PHASE2 | Metastatic Head and Neck Squamous Cell Carcinoma | RECRUITING | NCT06788990 |
| Pembrolizumab (KEYTRUDA®) | Other | Phase PHASE2 | Metastatic Head and Neck Squamous Cell Carcinoma | RECRUITING | NCT06788990 |
| Ficerafusp alfa | Other | Phase PHASE2 | Metastatic Head and Neck Squamous Cell Carcinoma | RECRUITING | NCT06788990 |
| Placebo | Other | Phase PHASE2 | Metastatic Head and Neck Squamous Cell Carcinoma | RECRUITING | NCT06788990 |
| Pembrolizumab (KEYTRUDA®) | Other | Phase PHASE2 | Metastatic Head and Neck Squamous Cell Carcinoma | RECRUITING | NCT06788990 |
| Ficerafusp alfa | Other | Phase PHASE2 | Metastatic Head and Neck Squamous Cell Carcinoma | RECRUITING | NCT06788990 |
| Pembrolizumab | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma | RECRUITING | NCT04429542 |
| BCA101 | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma | RECRUITING | NCT04429542 |
| Placebo | Other | Phase PHASE2 | Metastatic Head and Neck Squamous Cell Carcinoma | RECRUITING | NCT06788990 |
| Pembrolizumab (KEYTRUDA®) | Other | Phase PHASE2 | Metastatic Head and Neck Squamous Cell Carcinoma | RECRUITING | NCT06788990 |
| Ficerafusp alfa | Other | Phase PHASE2 | Metastatic Head and Neck Squamous Cell Carcinoma | RECRUITING | NCT06788990 |
| Pembrolizumab | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | RECRUITING | NCT07465276 |
| Ficerafusp alfa | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | RECRUITING | NCT07465276 |
| Ficerafusp alfa | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma | NOT_YET_RECRUITING | NCT07552558 |
| Pembrolizumab | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma | NOT_YET_RECRUITING | NCT07552558 |
| Hypofractionated Stereotactic Body Radiotherapy (SBRT) | Drug | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma | NOT_YET_RECRUITING | NCT07552558 |
| Ficerafusp alfa | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma | NOT_YET_RECRUITING | NCT07552558 |
| Pembrolizumab | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma | NOT_YET_RECRUITING | NCT07552558 |
| Hypofractionated Stereotactic Body Radiotherapy (SBRT) | Drug | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma | NOT_YET_RECRUITING | NCT07552558 |
| Ficerafusp alfa | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma | NOT_YET_RECRUITING | NCT07552558 |
| Pembrolizumab | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma | NOT_YET_RECRUITING | NCT07552558 |
| Hypofractionated Stereotactic Body Radiotherapy (SBRT) | Drug | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma | NOT_YET_RECRUITING | NCT07552558 |
| Ficerafusp alfa | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma | NOT_YET_RECRUITING | NCT07552558 |
| Pembrolizumab | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma | NOT_YET_RECRUITING | NCT07552558 |
| Hypofractionated Stereotactic Body Radiotherapy (SBRT) | Drug | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma | NOT_YET_RECRUITING | NCT07552558 |
| Ficerafusp alfa | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma | NOT_YET_RECRUITING | NCT07552558 |
| Pembrolizumab | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma | NOT_YET_RECRUITING | NCT07552558 |
| Hypofractionated Stereotactic Body Radiotherapy (SBRT) | Drug | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma | NOT_YET_RECRUITING | NCT07552558 |
| Ficerafusp alfa | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma | NOT_YET_RECRUITING | NCT07552558 |
| Pembrolizumab | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma | NOT_YET_RECRUITING | NCT07552558 |
| Hypofractionated Stereotactic Body Radiotherapy (SBRT) | Drug | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma | NOT_YET_RECRUITING | NCT07552558 |
| Ficerafusp alfa | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma | NOT_YET_RECRUITING | NCT07552558 |
| Pembrolizumab | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma | NOT_YET_RECRUITING | NCT07552558 |
| Hypofractionated Stereotactic Body Radiotherapy (SBRT) | Drug | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma | NOT_YET_RECRUITING | NCT07552558 |